Plus Therapeutics Highlights Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company specializing in targeted radiotherapeutics for central nervous system cancers, is set to present new data on its therapeutics and diagnostics programs for Leptomeningeal Metastases (LM) at the 2024 Society for Neuro-Oncology (SNO) / American Society for Clinical Oncology (ASCO) CNS Metastases Conference. The event will take place from August 8-10 in Denver, Colorado.

Dr. Marc H. Hedrick, President and CEO of Plus Therapeutics, emphasized the importance of the conference as a platform to showcase the company's progress in their LM therapeutics and diagnostics programs. The conference will attract key influencers and clinicians in the field, providing Plus Therapeutics with multiple opportunities to share their findings with the scientific community.

Key Events and Data Presentations:

1. Symposium:
- Title: “Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases”
- Date/Time: August 8, 2024, 6:15-7:15 p.m. MDT
- Location: Plaza Ballroom (DEF), Sheraton Denver Downtown Hotel
- Speakers:
- Greg Fuller, M.D., Ph.D., Plus Therapeutics Medical Director and VP of Medical Affairs
- Seema Nagpal, M.D., Clinical Professor, Neurology & Neurological Sciences, Stanford University
- Jonathan Yang, M.D., Ph.D., Associate Vice Chair for Clinical Research, NYU Langone Health’s Perlmutter Cancer Center
- Andrew Brenner, M.D., Ph.D., Professor, University of Texas Health, Science Center at San Antonio

2. Therapeutic Presentation:
- Title: “Phase 1 Dose Escalation of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for the Treatment of Leptomeningeal Metastases (LM): Ongoing Clinical Study Update for Initial Safety and Feasibility”
- Presenter: Andrew Brenner, M.D., Ph.D.
- Date/Time: August 9, 2024, 1:10-2:30 p.m. MDT
- Location: Plaza Ballroom (ABC)

3. Therapeutic Poster:
- Title: “Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastases Using Beta-Emission Radiopharmaceuticals”
- Presenter: Ande Bao, Ph.D., M.S., Assistant Professor, Case Western University
- Date/Time: August 8, 2024, 7:15-09:00 p.m. MDT
- Location: Plaza Exhibit Hall

4. Diagnostic Presentation:
- Title: “CSF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker Assessment in Clinical Management of Breast Cancer and Non-Small Cell Lung Cancer Patients with Leptomeningeal Disease (FORESEE Study)”
- Presenter: Priya Kumthekar, M.D., Associate Professor, Northwestern University Medical School
- Date/Time: August 10, 2024, 08:45-10:05 a.m. MDT
- Location: Plaza Ballroom (ABC)

5. Diagnostic Poster:
- Title: “The CNSide CSF Tumor Cell Detection Platform for Disease Management in Leptomeningeal Disease Patients”
- Presenter: Arushi Tripathy, M.D., Neurosurgery PGY-4 Resident, University of Michigan Medical School
- Date/Time: August 8, 2024, 7:15-9:00 p.m. MDT
- Location: Plaza Exhibit Hall

Leptomeningeal Metastases (LM) is a severe cancer complication where the primary cancer spreads to the cerebrospinal fluid (CSF) and the leptomeninges surrounding the brain and spinal cord. This condition is terminal in many cases, with very low survival rates.

Plus Therapeutics is focusing on Rhenium (186Re) obisbemeda, an innovative injectable radiotherapy formulated to deliver targeted, high-dose radiation to CNS tumors. This approach is believed to offer improved outcomes for CNS cancer patients by minimizing off-target risks.

The company is also highlighting the CNSide Test, a laboratory-developed test (LDT) that provides quantitative tumor cell capture and detection. This test helps in identifying actionable molecular treatment targets, providing a unique opportunity for guiding therapy selection and monitoring response in patients with metastatic cancer to the CNS.

Plus Therapeutics is committed to advancing its pipeline of product candidates, particularly for recurrent glioblastoma (GBM) and leptomeningeal metastases (LM), and has strategic partnerships to support the development and potential commercialization of its products.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!